Crispr Therapeutics announces new programs targeting refractory hypertension and acute hepatic porphyria
May 10, 2024
Crispr Therapeutics AG has expanded its in vivo pipeline with two new programs, which utilize lipid nanoparticle (LNP)-based delivery of CRISPR/Cas9 gene-editing cargo to the liver.
